Trial Profile

A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 29 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IPH 5301 (Primary) ; Paclitaxel (Primary) ; Trastuzumab (Primary)
Indications Advanced breast cancer; Carcinoma; Endometrial cancer; Gastric cancer; HER2 positive breast cancer; Lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer
Focus Adverse reactions; First in man
Acronyms CHANCES

Most Recent Events

22 Jun 2026 Status changed from recruiting to active, no longer recruiting.
20 Mar 2026 Planned End Date changed from 1 Feb 2026 to 1 Mar 2027.
19 Mar 2024 Planned End Date changed from 1 Feb 2025 to 1 Feb 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com